Pharmacokinetics of the novel atypical opioid tapentadol following oral and intravenous administration in dogs

Veterinary Journal

Volumn 194, Issue 3, 2012, Pages 309-313

  Giorgi, Mario ^a   Meizler, Alon ^b   Mills, Paul C ^b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Bioavailability; Dogs; MOR NRI; Pharmacokinetics; Tapentadol

Indexed keywords

TAPENTADOL; TRAMADOL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STRUCTURE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SEDATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANALGESICS, OPIOID; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOGS; FEMALE; HALF-LIFE; MALE; PHENOLS;

CANIS FAMILIARIS;

EID: 84872404286     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2012.05.019     Document Type: Article

References (38)

1. Afilalo M., Etropolski M.S., Kuperwasser B., Kelly K., Okamoto A., Van Hove I., Steup A., Lange B., Rauschkolb C., Haeussler J. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo-and active-controlled phase III study. Clinical Drug Investigation 2010, 30:489-505.
2. Clutton R.E. Opioid analgesia in horses. Veterinary Clinics of North America: Equine Practice 2010, 26:493-514.
3. Dickenson A.H., Suzuki R. Opioids in neuropathic pain: Clues from animal studies. European Journal of Pain 2005, 9:113-116.
4. Etropolski M., Kelly K., Okamoto A., Rauschkolb C. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. Advances in Therapy 2011, 28:401-417.
5. Fox M.S. Chronic Pain in Small Animal Medicine 2010, Mason Publishing, London, UK, pp. 113-137.
6. Gabrielsson J., Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications 2002, Swedish Pharmaceutical Press, Stockholm, Sweden, pp. 141-151.
7. Giorgi M. Pharmacokinetic differences of tramadol in several animal species and human beings. Journal of Veterinary Research 2008, 63:1-4.
8. Giorgi M. Tramadol vs. tapentadol: A new horizon in pain treatment?. American Journal of Animal and Veterinary Sciences 2012, 7:7-11.
9. Giorgi M., Del Carlo S., Saccomanni G., Łebkowska-Wieruszewska B., Turini V., Kowalski C. Biopharmaceutical profile of tramadol in the dog. Veterinary Research Communications 2009, 33:S189-S192.
10. Giorgi M., Meizler A., Mills P.C. Detection and quantification of the novel opioid drug tapentadol in canine plasma by HPLC with spectrofluorimetric detection: Development and validation of a new methodology. Journal of Pharmaceutical and Biomedical Analysis 2012, 67:148-153. 10.1016/j.jpba.2012.04.020.
11. Giorgi M., Saccomanni G., Lebkowska-Wieruszewska B., Kowalski C. Pharmacokinetic evaluation of tramadol and its major metabolites after single oral sustained tablet administration in the dog: A pilot study. The Veterinary Journal 2009, 180:253-255.
12. Giorgi M., Soldani G., Manera C., Ferrarini P.L., Sgorbini M., Saccomanni G. Pharmacokinetics of tramadol and its metabolites M1, M2 and M5 in horses following intravenous, immediate release (fasted/fed) and sustained release single dose administration. Journal of Equine Veterinary Science 2007, 27:481-488.
13. Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clinical Pharmacokinetics 2004, 43:879-923.
14. Jacqz E., Ward S., Johnson R., Schenker S., Gerkens J., Branch R.A. Extrahepatic glucuronidation of morphine in the dog. Drug Metabolism and Disposition 1986, 14:627-630.
15. Kleinert R., Lange C., Steup A., Black P., Goldberg J., Desjardins P. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: The results of a randomized, double-blind, placebo-controlled study. Anesthesia and Analgesia 2008, 107:2048-2055.
16. Kress H.G. Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally-acting analgesics on the horizon?. European Journal of Pain 2010, 14:781-783.
17. KuKanich B., Papich M.G. Opioid analgesic drug. Veterinary Pharmacology and Therapeutics 2009, 301-336. Wiley-Blackwell, Ames, USA. Nineth Ed.
18. KuKanich B., Papich M.G. Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. American Journal of Veterinary Research 2011, 72:256-262.
19. Oguri K., Hanioka N., Yoshimura H. Species differences in metabolism of codeine: Urinary excretion of codeine glucuronide, morphine-3-glucuronide and morphine-6-glucuronide in mice, rats, guinea pigs and rabbits. Xenobiotica 1990, 20:683-688.
20. Pascoe P.J. Opioid analgesics. Veterinary Clinics of North America: Small Animal Practice 2000, 30:757-772.
21. Pasero C. Tapentadol for multimodal pain management. Journal of PeriAnesthesia Nursing 2011, 26:343-346.
22. Pasero C., Quinn T.E., Portenoy R.K., McCaffery M., Rizos A. Opioid analgesics. Pain Assessment and Pharmacologic Management 2011, 277-622. Mosby Elsevier, St. Louis, MO, USA.
23. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. Journal of Pharmacology and Experimental Therapeutics 1992, 260:275-285.
24. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L., Jacoby H.I., Selve N. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. Journal of Pharmacology and Experimental Therapeutics 1993, 267:331-340.
25. Schiene K., De Vry J., Tzschentke T.M. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain. Journal of Pharmacology and Experimental Therapeutic 2011, 339:537-544.
26. Schröder W., Tzschentke T.M., Terlinden R., De Vry J., Jahnel U., Christoph T., Tallarida R.J. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. Journal of Pharmacology and Experimental Therapeutics 2011, 337. 312-120.
27. Scott L.J., Perry C.M. Tramadol: A review of its use in perioperative pain. Drugs 2000, 60:139-176.
28. Smit J.W., Oh C., Rengelshausen J., Terlinden R., Ravenstijn P.G., Wang S.S., Upmalis D., Mangold B. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: Results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy 2010, 30:25-34.
29. Soars M.G., Smith D.J., Riley R.J., Burchell B. Cloning and characterization of a canine UDP-glucuronosyltransferase. Archives of Biochemistry and Biophysics 2001, 391:218-224.
30. Terlinden R., Kogel B.Y., Englberger W., Tzschentke T.M. In vitro and in vivo characterization of tapentadol metabolites. Methods and Findings in Experimental Clinical Pharmacology 2010, 32:31-38.
31. Terlinden R., Ossig J., Fliegert F., Lange C., Göhler K. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. European Journal of Drug Metabolism and Pharmacokinetic 2007, 32:163-169.
32. Toutain P.L., Lees P. Integration and modelling of pharmacokinetic and pharmacodynamic data to optimize dosage regimens in veterinary medicine. Journal of Veterinary Pharmacology and Therapeutics 2004, 27:467-477.
33. Tzschentke T.M., De Vry J., Terlinden R., Hennies H.H., Lange C., Strassburger W., Haurand M., Kolb J., Schneider J., Buschmann H., Finkam M., Jahnel U., Friderichs E. Tapentadol hydrochloride: Analgesic mu-opioid receptor agonist noradrenaline reuptake inhibitor. Drugs of the Future 2006, 31:1053-1061.
34. Tzschentke T.M., Jahnel U., Kögel B., Christoph T., Englberger W., De Vry J., Schiene K., Okamoto A., Upmalis D., Weber H., Lange C., Stegmann J.U., Kleinert R. Tapentadol hydrochloride: A next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today 2009, 45:483-496.
35. Vadivelu N., Mitra S., Hines R.L. Peripheral opioid receptor agonists for analgesia: A comprehensive review. Journal of Opioid Management 2011, 7:55-68.
36. Valverde A., Cantwell S., Hernández J., Brotherson C. Effects of acepromazine on the incidence of vomiting associated with opioid administration in dogs. Veterinary Anaesthesia and Analgesia 2004, 31:40-45.
37. Wilder-Smith C.H., Bettiga A. The analgesic tramadol has minimal effect on gastrointestinal motor function. British Journal of Clinical Pharmacology 1997, 43:71-75.
38. Wilhorn S., Kraus C. In patients experiencing acute pain, how does the efficacy and gastrointestinal tolerability of tapentadol compare with oxycodone?. Evidence-Based Practice 2011, 14:14.